Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma

Published:2024-08 Issue:2 Volume:86 Page:183-184
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Drake Marcus J.^ORCID,Birder Lori A.

Publisher

Elsevier BV

Reference5 articles.

1. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma;Rosenberg;Ann Oncol,2023

2. Enfortumab vedotin in previously treated advanced urothelial carcinoma;Powles;N Engl J Med,2021

3. Neural control of the lower urinary tract: peripheral and spinal mechanisms;Birder;Neurourol Urodyn,2010

4. Factors influencing lower urinary tract symptoms in advanced cancer patients with chemotherapy induced peripheral neuropathy;Cho;Int Neurourol J,2018

5. Outcomes of a noninferiority randomised controlled trial of surgery for men with urodynamic stress incontinence after prostate surgery (MASTER);Abrams;Eur Urol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3